Showing 4811-4820 of 8837 results for "".
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- San Francisco Dermatologist Bill Kwan Featured in Third Albumhttps://practicaldermatology.com/news/san-francisco-dermatologist-bill-kwan-featured-in-third-album/2460773/As a dermatologist, Bill Kwan, MD plies his craft as the provider of both medical and aesthetic care to patients in San Francisco. As a vocalist, he plies his craft sharing the art of music. Dr. Kwan has released "No Ordinary Love: The Music of Sade." The third album that features Dr. K
- Burt's Bees Nature-Based Ingredients Protect Against Evolving Skincare Challengeshttps://practicaldermatology.com/news/burts-bees-nature-based-ingredients-protect-against-evolving-skincare-challenges/2460772/Burt's Bees bakuchiol bests retinol when it comes to promoting expression of certain anti-aging genes, according to a poster presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. And other new research supports the moisturization and skin barrier benefits
- Dermavant: Posters Unveil Additional Data for Once-Daily Topical Tapinarofhttps://practicaldermatology.com/news/dermavant-posters-unveil-additional-data-for-once-daily-topical-tapinarof/2460770/Dermavant Sciences will present data in poster form from its two pivotal phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, at AAD VMX 2021. Tapinarof is a novel, once-daily therapeutic aryl hydrocarbon recepto
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly select
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study
- GEMME Webinar Series to Assess Impact of Essential Mask Wearing on Skinhttps://practicaldermatology.com/news/gemme-webinar-series-to-assess-impact-of-essential-mask-wearing-on-skin/2460754/Assessing the impact of essential mask wearing, the first of a series of four webinars from GEMME (Galderma Excellence Multichannel Medical Education) launches next month. “Under the mask: the consequences of essential mask wearing,” will stream Saturday, May 8, with Drs. Lu
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- First Launch from FlawlessCanvas Now Availablehttps://practicaldermatology.com/news/first-launch-from-flawlesscanvas-now-available/2460750/Quantum Lift Reset Serum™ is now available from FlawlessCanvas, Inc., direct to its Facebook and Instagram followers. “The design of FlawlessCanvas Quantum Lift Reset Serum™ was based on